• An immunoglobulin G1 λ-monoclonal antibody that specifically binds to DLL4 and prevents its interaction with notch receptors
    • DLL4-notch signaling may mediate the resistance to anti-VEGF therapy, and the blockade of notch signaling may abolish resistance.
    • Currently under investigation in phase 1 clinical trial with solid tumors
    • Proposed phase 1 expansion dose: 100 to 150 mg IV every 3 weeks
    • Half-life: 13 days
    • Preliminary side effects: Fatigue, increased AST, GGT, and alkaline phosphatase, nausea, anemia, increased BNP, hypertension, headache
    (MedImmune, 2013)
    Other topics in Targeted and Immunotherapy Agents